Loading
Retinal Development and Disorders / Retinoids in Leukemia and Cellular Processes · Journal article
International Journal of Molecular Sciences · August 7, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review evaluating intracellular retinoid-binding proteins (CRBP, CRALBP, CRABP) as potential pharmacological targets in retinal, oncologic, and neurodegenerative disease. The authors synthesize structural biology, biochemical data, and early-stage pharmacological evidence to discuss druggability, identify selectivity challenges, and propose future directions for drug development, but report no clinical efficacy or trial outcomes.
Journal article.
Intracellular retinoid-binding proteins are directly implicated in inherited retinal dystrophies, retinoid-dependent cancers, and neurodegenerative diseases but have received comparatively little attention as pharmacological targets. High-resolution X-ray co-crystal structures have defined binding pocket architecture of CRBP, CRALBP, and CRABP, establishing a basis for structure-guided drug discovery. Known small-molecule modulators include the first-in-class CRBP1 inhibitor abn-CBD and next-generation non-retinoid scaffolds.
Intracellular retinoid-binding proteins are directly implicated in inherited retinal dystrophies, retinoid-dependent cancers, and neurodegenerative diseases but have received comparatively little attention as pharmacological targets.
The source did not state who this applies to in practice.
This is a narrative review article evaluating druggability of retinoid-binding proteins based on structural and biochemical evidence, raising questions about therapeutic potential rather than reporting clinical trial results or definitive efficacy data.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Intracellular retinoid-binding proteins, including cellular retinol-binding proteins (CRBPs) and cellular retinoic acid-binding proteins (CRABPs), belong to the intracellular lipid-binding protein (iLBP) family, whereas cellular retinaldehyde-binding protein (CRALBP) is a structurally distinct retinoid-binding protein belonging to the CRAL-TRIO protein family and functions as an active regulator of retinoid trafficking, metabolism, and signaling. Although these proteins are directly implicated in inherited retinal dystrophies, retinoid-dependent cancers, and neurodegenerative diseases, they have received comparatively little attention as pharmacological targets relative to the extracellular carrier Retinol-Binding Protein 4 (RBP4). High-resolution structural studies, including atomic-resolution X-ray co-crystal structures of protein–ligand complexes, have defined the binding pocket architecture of each protein and established a basis for structure-guided drug discovery. This review critically evaluates the druggability of CRBP, CRALBP, and CRABP by integrating structural, biochemical, and pharmacological evidence. We discuss known small-molecule modulators, including the first-in-class CRBP1 inhibitor abn-CBD and next-generation non-retinoid scaffolds, alongside gene therapy strategies targeting CRALBP deficiency. We further address the selectivity challenges inherent to the conserved iLBP fold and identify future directions for the development of isoform-selective therapeutics for retinal degeneration, oncology, and neurodegeneration.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.